With the availability of many immunosuppressive drugs for treatment of solid organ transplantation increase to a life span of patients who is receiving tacrolimus separately for End Stage of liver, heart and lung, kidney. But after all success of solid organ transplantation is purely dependent on proper course of immunosuppressive therapy. Tacrolimus is lactones antibiotic isolated from the fermentation of streptomyces tstkubaeis. This calcineurin inhibitor widely used for its immunosuppressive properties to increase patient survival and prevent graft function, organ rejection in solid organ transplant and graft-versus-host disease in transplant patients suppresses to enzyme for the growth of B cells and T cells. It was first approved for use to prevent graft rejection in 1994 for liver transplantation and in 1997 for kidney transplantation. The outcomes of this drug have varied due to differences in induction and maintenance therapy, drug dosing and monitoring. The aim of this study of an assessment and reporting of adverse drug reaction was to analyze the case reports of literature critically, conducted to monitor and evaluated the adverse events (AEs) and adverse drug reactions (ADRs) of immunosuppressive drug regimens, its causality, severity in therapy which is used various organ transplant patients and to document the pharmacotherapeutic actions taken for its management.
Introduction
Immunosuppressant drugs are a class of drugs that suppress, or reduce, the strength of the body"s immune system. Some of these drugs are used to make the body less likely to reject a transplanted organ, such as a liver, heart or kidney, pancreas, bone marrow. These drugs are called anti-rejection drugs.
Immunosuppressive drug Tacrolimus are given to organ transplant recipients in two phases" induction and maintenance therapy. the induction phase usually include short courses of various antibodies against T lymphocytes, along with high dose of steroids. These are generally followed in renal transplanted patients in whom newly transplanted kidney is highly susceptible to nephrotoxic injury, where in liver and heart transplanted patients the rationale of using this practice is to protect them with pre-existing renal insufficiency from further injuries 1 . The aim of maintenance immunosuppression is to avoid acute rejection, interstitial fibrosis and tubular atrophy and to improve overall graft and patients survival. The use of antibody therapy to provide enough immunosuppression is to delay the initiation of therapy with nephrotoxic calcineurin inhibitors.
Immunosuppressant drugs are used to treat autoimmune diseases. With an autoimmune disease, the immune system attacks the body"s own tissue. Because immunosuppressant drugs weaken the immune system, they suppress this reaction. This helps reduce the impact of the autoimmune disease on the body. Autoimmune diseases treated with immunosuppressant drugs. Almost every organ transplant patients who receives an organ transplant must take immunosuppressant drugs due to immune system sees a transplanted organ as a foreign mass. Drugs allow the transplanted organ to remain healthy and free from damage.
Immunosuppressant drugs weaken immune system to reduce body"s reaction to the foreign organ. National and international 5, 6 . Calcineurin . Excessive immunosuppression increases the risk of infectious, metabolic, and malignant complications, nephrotoxicity.
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Mechanism of action
Tacrolimus is an immunosuppressant. It is a microclide lactone with potent in vitro and in vivo immunosuppressive activity.
Studies suggest that tacrolimus inhibits the formation of cytotoxic lymphocytes which are regarded as being primarily responsible for graft rejection.Tacrolimus suppresses T -cell activation and T-helper-cell dependent B-cell proliferation, as well as formation of lymphokines such as interleukin-2 receptor [11] [12] [13] [14] [15] . , these drugs as immunophilin inhibits the activity of enzyme calcineurin and due to this issue, interrupts the calciumdependent signal-transduction pathway in T cells 17, 18, 19 . As a consequence of calcineurin inhibition, transcription of early Tcell-activation genes is suppressed, affecting production of IL-2
and other cytokines such as IL-3, interferon and tumor necrosis factor. In addition, calcineurin inhibition modulates cyclic adenosine monophosphate responsive element binding protein activity 20 (Fig 1) . 
Material and Methods
In various study the patients with solid organ transplantation who received tacrolimus mainly on the case report of literature and procedure of inclusion studies was based on the methods of a Non interventional prospective, observational case series, cohort technique study & descriptive analysis of the data was done. The study was performed for solid organ transplantation patient"s case report and characteristic summary of product were included in the study. 
Data Selection
Methodology
A total no of incident as AEs and ADRs included the pattern non serious listed, non serious unlisted ADRs, serious listed and serious unlisted ADRs. Tacrolimus package insert and information about pharmacovigilance program the case report as received from literature were entered in the data base using the dictionary that has hierarchical structure arranged by system-organ class.
Case report were scrutinized and the data was collected in a specially designed performa which included the following details: Exhaustive literature survey and detail study of case reports. Identification of suspected ADR reporting in case report.Interpretation and coding of adverse reaction descriptions as per MedDRA. Individual case causality assessment.This study were examined the case reporting patterns for known adverse drug interactions in the time period.
Results and Discussion
Patient Demographics: Out of total case reports of patients find out, Male predominates over female (Fig.2) . In this study, among 83 case report patients who were developed ADRs, (58%) were males and (42%) were females (Fig.3) . (Fig.4 -Fig.7 ). immunosuppressive strategies is required to achieve an ideal regimen, which would prolong allograft survival with minimal complications as ADRs.
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